ACE-167

ID: ace167

Aliases: testosterone peptide, RdVTQ-related tetrapeptide

Type: compound

Route/form: injection or route depends on studied product

Status: preclinical_research_lead

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, review

Linked sources: 2

Broad outcomes: Hormones / fertility / sexual health, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• 14-3-3epsilon/VDAC1 interaction
• Leydig cell steroidogenesis
• LH signal amplifier

Optimization domains

• testosterone
• fertility
• endocrine

Research basis

• Mechanistic lineage from TVS167 work makes the 14-3-3epsilon/VDAC1 target biologically interesting.
• If identity and delivery are confirmed, endogenous steroidogenesis without exogenous androgen replacement is a coherent goal.

Limits, risks, and missing evidence

• Published source support is for TVS167/RdVTQ-lineage mechanism, not a mature ACE-167 clinical product identity.
• No human clinical efficacy package found in this seed pass.

Risk flags

• identity uncertain
• endocrine
• no direct human data found

Linked papers, labels, and reviews

1. 14-3-3epsilon-VDAC1 interactions in androgen formation / TVS167 peptide
   preclinical / pubmed_tvs167_2014
   Foundational TVS167/RdVTQ-lineage mechanism used to rationalize ACE-167-like claims; not a direct clinical source for named ACE-167 products.
2. Mitochondrial protein import and the genesis of steroidogenic mitochondria
   review / pubmed_steroidogenic_transduceosome_2011
   Background on mitochondrial cholesterol import in steroidogenesis.